Devonian Health Group Inc. (TSXV:GSD)
Canada · Delayed Price · Currency is CAD | Market Cap | 27.66M -23.4% |
| Revenue (ttm) | 18.52M -23.0% |
| Net Income | -6.97M |
| EPS | -2.74 |
| Shares Out | 2.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 291 |
| Average Volume | 824 |
| Open | 9.99 |
| Previous Close | 10.00 |
| Day's Range | 9.99 - 10.00 |
| 52-Week Range | 5.10 - 15.00 |
| Beta | 1.40 |
| RSI | 42.35 |
| Earnings Date | Mar 27, 2026 |
About Devonian Health Group
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatm... [Read more]
Financial Performance
In fiscal year 2025, Devonian Health Group's revenue was 23.59 million, an increase of 22.19% compared to the previous year's 19.31 million. Losses were -6.01 million, 229.1% more than in 2024.
Financial StatementsNews
Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update
Company continues preclinical studies for Thykamine™ in MASH and Fibrosis, furthering the understanding of Thykamine™'s mechanism of action. Thykamine™: A New Player in the Field of Anti-Inflammatory ...
Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed...
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
QUEBEC CITY — Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the “Exchange”) has approved its application for reinstatemen...
Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis
Statistically significant changes in fibrosis genes following three weeks of treatment with Thykamine™ Genes expression changes potentially expand the anti-fibrotic effects of Thykamine™ to fibrotic d...
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
QUEBEC CITY — Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announce...
Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study
In vitro study demonstrated superior potency of Thykamine™ against various corticosteroids and a phosphodiesterase inhibitor Supports the clinical efficacy results of Thykamine™ in previous and ongoin...